Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q4 2022 call → NOWe need to determine if management explains the company's business direction by narrating what its counterparties are doing and scaling, with the three conditions met. Let's analyze the transcript. The question asks: "On this call, does management explain where the company's business is going by NARRATING WHAT ITS COUNTERPARTIES ARE THEMSELVES DOING AND SCALING — that is, does a substantial part of management's forward account consist of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, licensees, distributors, payers, operators, or programs the company ALREADY SUPPLIES OR SERVES, such that the company's own coming volume is presented as a consequence of those parties' own trajectories rather than of the company's selling effort?" We need to look for instances where management talks about specific counterparties' own growth trajectories as the driver of ADM's future results. The transcript includes discussions about various segments. Let's scan. In the opening remarks, Juan Luciano talks about productivity, innovation, and strategic growth platforms. He mentions decarbonization, regenerative agriculture, and partnerships like with Pepsi (regenerative agriculture agreement) and LG Chem (BioSolutions joint venture). But are these described as counterparties scaling their own operations? He says: "like the ingredients we will sell to Pepsi from the regenerative agriculture agreement we announced last year" – that's a specific customer, but is it described as Pepsi's own trajectory? Not really. He also mentions "joint ventures like with LG Chem" – but again, not detailing LG Chem's own expansion. Later, in the Q&A, there are questions about Nutrition, Ag Services, etc. Let's look for any specific counterparty narratives. In the answer about Nutrition, Vikram says: "we talked about the strongest-ever pipeline in the Human Nutrition business and very strong win rates. So across every category that we play in, almost we’ve got strong demand." That's about demand generally, not specific counterparties scaling. In the answer about crush margins, Juan mentions "we are also going to have this year that we didn’t have last year, better canola margins." That's about market conditions. There is mention of "renewable diesel" demand, but that's a broad market trend.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.